Abstract Library

#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites

Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Mamodaly M, Chen R, Cazes A, Guedj N, Deschamps L,

Keywords: Neuroendocrine markers, Chromogranin A, Chromogranin B, INSM1,

#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells

Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Balasundaram P, Beaumont N, Liang S, Cuenco J, Lu X,

Keywords: neuroendocrine tumour, biomarkers, signalling,

#1804 Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT

Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ferolla P, Berruti A, Fazio N, Mazzanti P, Houchard A,

Keywords: Temozolomide, lanreotide,

#1757 Therapeutic Strategies in Patients with Neuroendocrine Neoplasm: 30 Month Follow-Up pf Long Survivors from EPH Mostaganem and EHU Oran Medical Oncology

Introduction: Neuro docrine tumors are poorly known and infrequent tumors are, most of the time, diagnosed late, often occurring between the age of 40 and 60.They mainly appear in the gastro intestinal system, pancreas, bronchi, lungs, thymus and thyroid.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Bengueddach A, Kehili H, Negadi S, Yamouni M, Malika K,

Keywords: Neuroendocrine tumors, metastasis, somatostatin analogs,

#1547 Neuroendocrine Tumours of the Thymus: A Report of Four Cases

Introduction: Neuroendocrine tumours of the thymus (thymic carcinoids) are a rare group of malignancies with a reported incidence of about 1 in 5 million. Over a ten year period in our institution, covering a population of 3.5 million, there had only been two confirmed cases.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Richardson C, Henley G, Jones C, Turner R, Anthoney A,

Keywords: -,